Extrapulmonary small cell carcinoma: Single center experience with 61 patients

Lee, Sung Sook; Lee, Jae‐Lyun; Ryu, Min‐Hee; Chang, Heung Moon; Kim, Tae Won; Kim, Woo Kun; Lee, Jung Shin; Jang, Se-Jin; Khang, Shin Kwang; Kang, Yoon‐Koo

doi:10.1080/02841860601071893

Cited by 80 publications

(39 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, the most common primary sites of the EP-NECs were the stomach, pancreas, and esophagus. On the other hand, relatively few patients had tumors arising in the reproductive tract, breast, or head and neck region, which have been reported to be associated with a better prognosis [4,9,10,11,12]. At our institution, genitourinary EP-NECs tend to be resected, and head and neck EP-NECs are often treated using chemoradiotherapy.…”

Section: Discussionmentioning

confidence: 99%

“…The definition of NEC refers to neoplasms previously classified as small-cell carcinoma or poorly differentiated (neuro)endocrine carcinoma (PDNEC). Since the first report of ‘extrapulmonary oat cell carcinoma’ of the mediastinum by Duguid and Kennedy [3 ]in 1930, extrapulmonary NECs (EP-NECs) have been reported to arise in a variety of organs, such as the gastrointestinal tract, pancreas, head and neck region, or urogenital tract [4,5,6,7,8,9,10,11,12,13,14,15,16]. EP-NECs are a fairly rare, heterogeneous disease entity, and no standard treatment has been established [17,18].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of Chemotherapeutic Treatment Outcomes of Advanced Extrapulmonary Neuroendocrine Carcinomas and Advanced Small-Cell Lung Carcinoma

Terashima¹,

Morizane²,

Hiraoka

et al. 2012

Neuroendocrinology

View full text Add to dashboard Cite

Background: The chemotherapy for small-cell lung carcinoma (SCLC) has been adopted for advanced extrapulmonary neuroendocrine carcinomas (EP-NECs). The aim of this study was to clarify the efficacy of standard SCLC regimens when used to treat EP-NECs and to compare the outcome with that for SCLC. Methods: We reviewed the medical records of 136 patients (41 with EP-NEC and 95 with SCLC) who were treated using a platinum-containing regimen for advanced disease between January 2000 and October 2008 at our hospital. Results: The primary site of the EP-NEC was the gastrointestinal tract in 18 patients (GI tract group); the liver, biliary tract or pancreas in 16 patients (HBP group), and other sites in 7 patients (‘others’ group). The response rate in the SCLC patients was 77.8%, and the response rate in the EP-NEC patients was 30.8% (37.5% in the GI tract group, 12.5% in the HBP group, and 57.1% in the ‘others’ group). The median survival time for the SCLC patients was 13.6 months, while that for the EP-NEC patients was 9.2 months (14.9 months in the GI tract group, 7.8 months in the HBP group, and 8.9 months in the ‘others’ group). A multivariate analysis demonstrated that a poor performance status, liver involvement, and the treatment regimen were independent unfavorable prognostic factors. Conclusion: The response rate and prognosis of the patients with advanced EP-NECs were worse than those of the patients with SCLC in this study. The Eastern Cooperative Oncology Group performance status, liver involvement, and treatment regimen had a larger impact on the prognosis than the primary tumor site, as demonstrated by multivariate analysis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Comparison of Chemotherapeutic Treatment Outcomes of Advanced Extrapulmonary Neuroendocrine Carcinomas and Advanced Small-Cell Lung Carcinoma

Terashima¹,

Morizane²,

Hiraoka

et al. 2012

Neuroendocrinology

View full text Add to dashboard Cite

show abstract

“…Pulmonary small-cell carcinoma prognosis is dismal and the outcomes regarding extra-pulmonary disease are equally poor, with 5-year survival rates of 11 to 13% (12)(13)(14)(15). Combined RT and ChT are considered to be the standard approach and surgery is reserved for limited stage initial and range from surgery to isolated or combined RT and ChT (9,10,17).…”

Section: Discussionmentioning

confidence: 99%

Small-Cell Neuroendocrine Carcinoma Originating From the Nasopharynx: Report of a Rare Case

Aguiar

Jacóme

Azevedo

et al. 2015

Rep Radiother Oncol

View full text Add to dashboard Cite

Introduction: Extrapulmonary small-cell carcinoma, neuroendocrine type is uncommon, particularly in the head and neck region. It represents an extremely rare finding when originating from the nasopharynx, and so far only five cases have been reported. Case Presentation: The authors present a case of a female patient with this tumor type, and describe a treatment strategy that combined radiotherapy and chemotherapy. Conclusions: Persistent disease was documented ten months after treatment completion.

show abstract

“…The median age of EPSCC patients was 53-72 years, and the male-to-female ratio was 1.03-1.4:1 [3,4,5,15,16,17]. Similar to SCLC, EPSCC includes 2 stages.…”

Section: Discussionmentioning

confidence: 99%

“…Extrapulmonary small cell carcinoma (EPSCC), which accounts for only 2.5-4% of all small cell carcinomas, occurs in many extrapulmonary sites such as the gastrointestinal tract, the head and neck, and the genitourinary system [1,2,3,4,5]. EPSCC of unknown primary has also been reported [6] and accounts for 8-31%.…”

Section: Introductionmentioning

confidence: 99%

Primary Intracranial Small Cell Carcinoma: A Case Report and Review of the Literature

et al. 2013

View full text Add to dashboard Cite

Background: Extrapulmonary small cell carcinoma is a distinct clinicopathological entity accounting for only 2.5-4% of small cell carcinomas. Here we present a case of primary intracranial small cell carcinoma. Case Report: A 69-year-old woman with an isolated brain lesion presented with progressive headaches, confusion, nausea, and vomiting. A magnetic resonance imaging scan of the brain revealed a 4 × 3 × 5-cm solitary cystic tumor in the right frontoparietal lobe, accompanied by a midline shift. The mass was resected and pathologically proven to be a small cell carcinoma. The patient was given adjuvant radiotherapy but refused any chemotherapy. At the 12-month follow-up the patient was alive and well. Conclusion: Primary intracranial small cell carcinoma presenting as an isolated lesion is extremely rare. While there are no standard treatment guidelines for these patients, the authors believe multimodality treatment including tumorectomy and postoperative radiotherapy should be recommended.

show abstract

Extrapulmonary small cell carcinoma: Single center experience with 61 patients

Cited by 80 publications

References 23 publications

Comparison of Chemotherapeutic Treatment Outcomes of Advanced Extrapulmonary Neuroendocrine Carcinomas and Advanced Small-Cell Lung Carcinoma

Comparison of Chemotherapeutic Treatment Outcomes of Advanced Extrapulmonary Neuroendocrine Carcinomas and Advanced Small-Cell Lung Carcinoma

Small-Cell Neuroendocrine Carcinoma Originating From the Nasopharynx: Report of a Rare Case

Primary Intracranial Small Cell Carcinoma: A Case Report and Review of the Literature

Contact Info

Product

Resources

About